CING — Cingulate Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1862150 ·
Last close
$5.26
Market Cap
$76.49M
52W High
$11.89
52W Low
$3.16
ADV30
230,007
Next earnings
—
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,490,660 -7,731,397 28,150,677 23,185,900 7,383,547
Jun 2026 0 — -5,414,975 -5,870,264 33,066,321 28,402,819 9,599,286
Mar 2026 0 — -7,923,318 -9,312,089 30,861,701 25,893,210 11,996,835
Dec 2025 0 — -5,585,948 -6,272,910 15,073,263 10,953,383 12,564,356

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,654,108
Investing CF
$-284,476
Financing CF
$40,441,220
CapEx
$-284,476
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-147,557,384
Inventory
—
Receivables
$38,447
ST Investments
—
EBIT TTM
$-24,919,785
Pretax Income TTM
$-28,796,325
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -19,938,057 -22,449,911 15,073,263 12,564,356 2,508,907 -17,245,182
Dec 2024 0 -15,645,265 -16,559,605 14,864,489 7,408,984 7,455,505 -18,451,387
Dec 2023 0 -22,759,304 -23,534,947 3,491,436 10,360,865 -6,869,429 -15,034,543
Dec 2022 0 -17,502,280 -17,676,232 11,405,057 7,523,035 3,882,022 -15,882,808

TTM Snapshot

Revenues TTM
$3,502,172
NetIncome TTM
$-29,040,838
OpCashFlow TTM
—
Assets (Latest)
$33,066,321
Forward EPS
$-0.88

Max Pain — expiry 2027-02-19

max pain strike: $5.00 · spot: $5.26 · call oi: 8,803 · put oi: 82
Expected Move to 2027-02-19: ±$3.80 (72.24%) — implied range $1.46 – $9.06 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RACC Research Alliance Corp III $77.83M $10.01 —
ZOMDF Zomedica Corp. $78.59M $0.08 —
DERM Journey Medical Corp $78.92M $3.55 —
NKTX Nkarta, Inc. $80.22M $1.12 —
ZYBT Zhengye Biotechnology Holding Ltd $72.03M $1.52 —

News headlines (Yahoo Finance, 1h cache)

Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
2026-11-19 14:29 · Yahoo
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
2026-11-13 21:45 · Yahoo
Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King
2026-11-10 13:00 · Yahoo
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
2026-09-17 12:05 · Yahoo
CING: Second Quarter Results
2026-08-19 15:13 · Yahoo
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
2026-08-13 12:30 · Yahoo
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-07-02 12:30 · Yahoo
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
2026-05-14 12:00 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
2026-04-06 20:34 · Yahoo
CING: Building Its Cash Position
2026-05-19 09:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.